nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—urinary bladder cancer	0.344	0.678	CbGaD
Pomalidomide—PTGS2—urinary bladder cancer	0.164	0.322	CbGaD
Pomalidomide—ABCB1—Mitomycin—urinary bladder cancer	0.0608	0.227	CbGbCtD
Pomalidomide—PTGS2—Cisplatin—urinary bladder cancer	0.0385	0.144	CbGbCtD
Pomalidomide—PTGS2—Etoposide—urinary bladder cancer	0.0378	0.141	CbGbCtD
Pomalidomide—CYP3A4—Thiotepa—urinary bladder cancer	0.0276	0.103	CbGbCtD
Pomalidomide—ABCB1—Gemcitabine—urinary bladder cancer	0.0175	0.0652	CbGbCtD
Pomalidomide—CYP1A2—Fluorouracil—urinary bladder cancer	0.0171	0.0638	CbGbCtD
Pomalidomide—CYP1A2—Etoposide—urinary bladder cancer	0.0143	0.0532	CbGbCtD
Pomalidomide—ABCB1—Cisplatin—urinary bladder cancer	0.0127	0.0474	CbGbCtD
Pomalidomide—ABCB1—Etoposide—urinary bladder cancer	0.0125	0.0466	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—urinary bladder cancer	0.00852	0.0318	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—urinary bladder cancer	0.00825	0.0308	CbGbCtD
Pomalidomide—CYP3A4—Etoposide—urinary bladder cancer	0.00748	0.0279	CbGbCtD
Pomalidomide—CYP3A4—Doxorubicin—urinary bladder cancer	0.0051	0.019	CbGbCtD
Pomalidomide—TNF—vagina—urinary bladder cancer	0.00307	0.095	CbGeAlD
Pomalidomide—CRBN—prostate gland—urinary bladder cancer	0.00298	0.0919	CbGeAlD
Pomalidomide—CYP1A2—urine—urinary bladder cancer	0.00272	0.0842	CbGeAlD
Pomalidomide—CRBN—seminal vesicle—urinary bladder cancer	0.00252	0.0778	CbGeAlD
Pomalidomide—CRBN—renal system—urinary bladder cancer	0.00203	0.0627	CbGeAlD
Pomalidomide—CRBN—urethra—urinary bladder cancer	0.00199	0.0616	CbGeAlD
Pomalidomide—TNF—lymph node—urinary bladder cancer	0.00199	0.0614	CbGeAlD
Pomalidomide—CYP3A4—urine—urinary bladder cancer	0.00197	0.0609	CbGeAlD
Pomalidomide—CRBN—female reproductive system—urinary bladder cancer	0.00162	0.0502	CbGeAlD
Pomalidomide—CRBN—vagina—urinary bladder cancer	0.00147	0.0454	CbGeAlD
Pomalidomide—Thalidomide—TNF—urinary bladder cancer	0.00143	0.441	CrCbGaD
Pomalidomide—Lenalidomide—PTGS2—urinary bladder cancer	0.00113	0.35	CrCbGaD
Pomalidomide—CRBN—lymph node—urinary bladder cancer	0.00095	0.0294	CbGeAlD
Pomalidomide—PTGS2—prostate gland—urinary bladder cancer	0.00081	0.025	CbGeAlD
Pomalidomide—PTGS2—seminal vesicle—urinary bladder cancer	0.000685	0.0212	CbGeAlD
Pomalidomide—Thalidomide—PTGS2—urinary bladder cancer	0.00068	0.209	CrCbGaD
Pomalidomide—CYP1A2—renal system—urinary bladder cancer	0.000667	0.0206	CbGeAlD
Pomalidomide—PTGS2—epithelium—urinary bladder cancer	0.000595	0.0184	CbGeAlD
Pomalidomide—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000574	0.0177	CbGeAlD
Pomalidomide—PTGS2—renal system—urinary bladder cancer	0.000552	0.0171	CbGeAlD
Pomalidomide—PTGS2—urethra—urinary bladder cancer	0.000542	0.0168	CbGeAlD
Pomalidomide—ABCB1—prostate gland—urinary bladder cancer	0.000501	0.0155	CbGeAlD
Pomalidomide—CYP3A4—renal system—urinary bladder cancer	0.000483	0.0149	CbGeAlD
Pomalidomide—PTGS2—female reproductive system—urinary bladder cancer	0.000442	0.0137	CbGeAlD
Pomalidomide—ABCB1—seminal vesicle—urinary bladder cancer	0.000424	0.0131	CbGeAlD
Pomalidomide—PTGS2—vagina—urinary bladder cancer	0.0004	0.0124	CbGeAlD
Pomalidomide—CYP3A4—female reproductive system—urinary bladder cancer	0.000386	0.0119	CbGeAlD
Pomalidomide—ABCB1—epithelium—urinary bladder cancer	0.000368	0.0114	CbGeAlD
Pomalidomide—ABCB1—renal system—urinary bladder cancer	0.000342	0.0106	CbGeAlD
Pomalidomide—ABCB1—urethra—urinary bladder cancer	0.000336	0.0104	CbGeAlD
Pomalidomide—ABCB1—female reproductive system—urinary bladder cancer	0.000274	0.00845	CbGeAlD
Pomalidomide—PTGS2—lymph node—urinary bladder cancer	0.000259	0.00799	CbGeAlD
Pomalidomide—ABCB1—vagina—urinary bladder cancer	0.000247	0.00765	CbGeAlD
Pomalidomide—ABCB1—lymph node—urinary bladder cancer	0.00016	0.00495	CbGeAlD
Pomalidomide—Muscular weakness—Epirubicin—urinary bladder cancer	0.000138	0.0011	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000138	0.0011	CcSEcCtD
Pomalidomide—Pain—Gemcitabine—urinary bladder cancer	0.000137	0.0011	CcSEcCtD
Pomalidomide—Constipation—Gemcitabine—urinary bladder cancer	0.000137	0.0011	CcSEcCtD
Pomalidomide—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000137	0.0011	CcSEcCtD
Pomalidomide—Pancytopenia—Methotrexate—urinary bladder cancer	0.000137	0.0011	CcSEcCtD
Pomalidomide—Asthenia—Thiotepa—urinary bladder cancer	0.000137	0.00109	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000136	0.00109	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000136	0.00109	CcSEcCtD
Pomalidomide—Infection—Etoposide—urinary bladder cancer	0.000136	0.00109	CcSEcCtD
Pomalidomide—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000135	0.00108	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—urinary bladder cancer	0.000135	0.00108	CcSEcCtD
Pomalidomide—Pruritus—Thiotepa—urinary bladder cancer	0.000135	0.00108	CcSEcCtD
Pomalidomide—Pain—Fluorouracil—urinary bladder cancer	0.000135	0.00108	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—urinary bladder cancer	0.000135	0.00107	CcSEcCtD
Pomalidomide—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000134	0.00107	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000134	0.00107	CcSEcCtD
Pomalidomide—Dyspnoea—Cisplatin—urinary bladder cancer	0.000133	0.00107	CcSEcCtD
Pomalidomide—Skin disorder—Etoposide—urinary bladder cancer	0.000133	0.00106	CcSEcCtD
Pomalidomide—Dry skin—Doxorubicin—urinary bladder cancer	0.000133	0.00106	CcSEcCtD
Pomalidomide—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000132	0.00106	CcSEcCtD
Pomalidomide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000132	0.00106	CcSEcCtD
Pomalidomide—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000132	0.00105	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—urinary bladder cancer	0.000131	0.00104	CcSEcCtD
Pomalidomide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000131	0.00104	CcSEcCtD
Pomalidomide—Decreased appetite—Cisplatin—urinary bladder cancer	0.00013	0.00104	CcSEcCtD
Pomalidomide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00013	0.00104	CcSEcCtD
Pomalidomide—Bronchitis—Epirubicin—urinary bladder cancer	0.00013	0.00104	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—urinary bladder cancer	0.000129	0.00103	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000129	0.00103	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000129	0.00103	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—urinary bladder cancer	0.000129	0.00103	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—urinary bladder cancer	0.000129	0.00103	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—urinary bladder cancer	0.000128	0.00102	CcSEcCtD
Pomalidomide—Pain—Cisplatin—urinary bladder cancer	0.000128	0.00102	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000128	0.00102	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000128	0.00102	CcSEcCtD
Pomalidomide—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000127	0.00101	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—urinary bladder cancer	0.000127	0.00101	CcSEcCtD
Pomalidomide—Neutropenia—Epirubicin—urinary bladder cancer	0.000126	0.00101	CcSEcCtD
Pomalidomide—Dizziness—Thiotepa—urinary bladder cancer	0.000126	0.00101	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000126	0.001	CcSEcCtD
Pomalidomide—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000125	0.000997	CcSEcCtD
Pomalidomide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000123	0.000985	CcSEcCtD
Pomalidomide—Weight increased—Epirubicin—urinary bladder cancer	0.000123	0.000982	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—urinary bladder cancer	0.000122	0.000976	CcSEcCtD
Pomalidomide—Dyspnoea—Etoposide—urinary bladder cancer	0.000122	0.000976	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000122	0.000973	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000122	0.000972	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—urinary bladder cancer	0.000121	0.00097	CcSEcCtD
Pomalidomide—Vomiting—Thiotepa—urinary bladder cancer	0.000121	0.000969	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—urinary bladder cancer	0.000121	0.000968	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—urinary bladder cancer	0.00012	0.000962	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—urinary bladder cancer	0.00012	0.000962	CcSEcCtD
Pomalidomide—Rash—Thiotepa—urinary bladder cancer	0.00012	0.000961	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—urinary bladder cancer	0.00012	0.00096	CcSEcCtD
Pomalidomide—Dermatitis—Thiotepa—urinary bladder cancer	0.00012	0.00096	CcSEcCtD
Pomalidomide—Headache—Thiotepa—urinary bladder cancer	0.00012	0.000955	CcSEcCtD
Pomalidomide—Decreased appetite—Etoposide—urinary bladder cancer	0.000119	0.000952	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000119	0.000948	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—urinary bladder cancer	0.000118	0.000946	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000118	0.000945	CcSEcCtD
Pomalidomide—Body temperature increased—Cisplatin—urinary bladder cancer	0.000118	0.000945	CcSEcCtD
Pomalidomide—Fatigue—Etoposide—urinary bladder cancer	0.000118	0.000944	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000118	0.000943	CcSEcCtD
Pomalidomide—Pain—Etoposide—urinary bladder cancer	0.000117	0.000936	CcSEcCtD
Pomalidomide—Constipation—Etoposide—urinary bladder cancer	0.000117	0.000936	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000117	0.000935	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—urinary bladder cancer	0.000117	0.000934	CcSEcCtD
Pomalidomide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000116	0.000929	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000116	0.000928	CcSEcCtD
Pomalidomide—Asthenia—Gemcitabine—urinary bladder cancer	0.000115	0.00092	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000114	0.000912	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000114	0.00091	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—urinary bladder cancer	0.000114	0.000909	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—urinary bladder cancer	0.000114	0.000908	CcSEcCtD
Pomalidomide—Pruritus—Gemcitabine—urinary bladder cancer	0.000114	0.000907	CcSEcCtD
Pomalidomide—Nausea—Thiotepa—urinary bladder cancer	0.000113	0.000905	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—urinary bladder cancer	0.000113	0.000905	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—urinary bladder cancer	0.000113	0.000903	CcSEcCtD
Pomalidomide—Feeling abnormal—Etoposide—urinary bladder cancer	0.000113	0.000902	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000113	0.000901	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—urinary bladder cancer	0.000112	0.000896	CcSEcCtD
Pomalidomide—Pruritus—Fluorouracil—urinary bladder cancer	0.000112	0.000892	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000111	0.00089	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—urinary bladder cancer	0.000111	0.00089	CcSEcCtD
Pomalidomide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00011	0.00088	CcSEcCtD
Pomalidomide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00011	0.000877	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—urinary bladder cancer	0.00011	0.000875	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000109	0.000873	CcSEcCtD
Pomalidomide—Body temperature increased—Etoposide—urinary bladder cancer	0.000108	0.000865	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000108	0.000865	CcSEcCtD
Pomalidomide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000108	0.000863	CcSEcCtD
Pomalidomide—Asthenia—Cisplatin—urinary bladder cancer	0.000107	0.000857	CcSEcCtD
Pomalidomide—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000107	0.000857	CcSEcCtD
Pomalidomide—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000107	0.000853	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000107	0.000851	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000106	0.000849	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—urinary bladder cancer	0.000106	0.000847	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000105	0.000842	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—urinary bladder cancer	0.000105	0.00084	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—urinary bladder cancer	0.000105	0.000837	CcSEcCtD
Pomalidomide—Dizziness—Fluorouracil—urinary bladder cancer	0.000104	0.000834	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000104	0.000832	CcSEcCtD
Pomalidomide—Chills—Methotrexate—urinary bladder cancer	0.000104	0.000828	CcSEcCtD
Pomalidomide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000102	0.000818	CcSEcCtD
Pomalidomide—Vomiting—Gemcitabine—urinary bladder cancer	0.000102	0.000815	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—urinary bladder cancer	0.000101	0.000809	CcSEcCtD
Pomalidomide—Rash—Gemcitabine—urinary bladder cancer	0.000101	0.000808	CcSEcCtD
Pomalidomide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000101	0.000808	CcSEcCtD
Pomalidomide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000101	0.000807	CcSEcCtD
Pomalidomide—Malnutrition—Methotrexate—urinary bladder cancer	0.000101	0.000804	CcSEcCtD
Pomalidomide—Headache—Gemcitabine—urinary bladder cancer	0.000101	0.000803	CcSEcCtD
Pomalidomide—Cardiac disorder—Epirubicin—urinary bladder cancer	0.0001	0.000802	CcSEcCtD
Pomalidomide—Vomiting—Fluorouracil—urinary bladder cancer	0.0001	0.000802	CcSEcCtD
Pomalidomide—Rash—Fluorouracil—urinary bladder cancer	9.95e-05	0.000795	CcSEcCtD
Pomalidomide—Dermatitis—Fluorouracil—urinary bladder cancer	9.94e-05	0.000794	CcSEcCtD
Pomalidomide—Headache—Fluorouracil—urinary bladder cancer	9.89e-05	0.00079	CcSEcCtD
Pomalidomide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	9.88e-05	0.000789	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—urinary bladder cancer	9.86e-05	0.000787	CcSEcCtD
Pomalidomide—Asthenia—Etoposide—urinary bladder cancer	9.83e-05	0.000786	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—urinary bladder cancer	9.83e-05	0.000785	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—urinary bladder cancer	9.81e-05	0.000784	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—urinary bladder cancer	9.81e-05	0.000783	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—urinary bladder cancer	9.75e-05	0.000779	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—urinary bladder cancer	9.73e-05	0.000777	CcSEcCtD
Pomalidomide—Chills—Epirubicin—urinary bladder cancer	9.7e-05	0.000775	CcSEcCtD
Pomalidomide—Pruritus—Etoposide—urinary bladder cancer	9.7e-05	0.000775	CcSEcCtD
Pomalidomide—Nausea—Gemcitabine—urinary bladder cancer	9.53e-05	0.000762	CcSEcCtD
Pomalidomide—Vomiting—Cisplatin—urinary bladder cancer	9.51e-05	0.00076	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—urinary bladder cancer	9.47e-05	0.000757	CcSEcCtD
Pomalidomide—Rash—Cisplatin—urinary bladder cancer	9.43e-05	0.000753	CcSEcCtD
Pomalidomide—Dermatitis—Cisplatin—urinary bladder cancer	9.42e-05	0.000753	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—urinary bladder cancer	9.41e-05	0.000752	CcSEcCtD
Pomalidomide—Diarrhoea—Etoposide—urinary bladder cancer	9.38e-05	0.000749	CcSEcCtD
Pomalidomide—Nausea—Fluorouracil—urinary bladder cancer	9.37e-05	0.000749	CcSEcCtD
Pomalidomide—Anaemia—Methotrexate—urinary bladder cancer	9.3e-05	0.000743	CcSEcCtD
Pomalidomide—Cardiac disorder—Doxorubicin—urinary bladder cancer	9.29e-05	0.000742	CcSEcCtD
Pomalidomide—Back pain—Epirubicin—urinary bladder cancer	9.11e-05	0.000727	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—urinary bladder cancer	9.08e-05	0.000725	CcSEcCtD
Pomalidomide—Dizziness—Etoposide—urinary bladder cancer	9.06e-05	0.000724	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—urinary bladder cancer	9.05e-05	0.000723	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—urinary bladder cancer	9.04e-05	0.000722	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	9.02e-05	0.00072	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—urinary bladder cancer	9e-05	0.000719	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—urinary bladder cancer	8.98e-05	0.000717	CcSEcCtD
Pomalidomide—Nausea—Cisplatin—urinary bladder cancer	8.89e-05	0.00071	CcSEcCtD
Pomalidomide—Cough—Methotrexate—urinary bladder cancer	8.78e-05	0.000701	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—urinary bladder cancer	8.77e-05	0.0007	CcSEcCtD
Pomalidomide—Vomiting—Etoposide—urinary bladder cancer	8.71e-05	0.000696	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—urinary bladder cancer	8.71e-05	0.000696	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—urinary bladder cancer	8.7e-05	0.000695	CcSEcCtD
Pomalidomide—Rash—Etoposide—urinary bladder cancer	8.64e-05	0.00069	CcSEcCtD
Pomalidomide—Dermatitis—Etoposide—urinary bladder cancer	8.63e-05	0.00069	CcSEcCtD
Pomalidomide—Headache—Etoposide—urinary bladder cancer	8.59e-05	0.000686	CcSEcCtD
Pomalidomide—Arthralgia—Methotrexate—urinary bladder cancer	8.56e-05	0.000684	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.5e-05	0.000679	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—urinary bladder cancer	8.46e-05	0.000676	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—urinary bladder cancer	8.43e-05	0.000673	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—urinary bladder cancer	8.43e-05	0.000673	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—urinary bladder cancer	8.37e-05	0.000669	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—urinary bladder cancer	8.28e-05	0.000661	CcSEcCtD
Pomalidomide—Cough—Epirubicin—urinary bladder cancer	8.21e-05	0.000656	CcSEcCtD
Pomalidomide—Infection—Methotrexate—urinary bladder cancer	8.16e-05	0.000651	CcSEcCtD
Pomalidomide—Nausea—Etoposide—urinary bladder cancer	8.14e-05	0.00065	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—urinary bladder cancer	8.05e-05	0.000643	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—urinary bladder cancer	8.05e-05	0.000643	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.04e-05	0.000642	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—urinary bladder cancer	8.01e-05	0.00064	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—urinary bladder cancer	7.99e-05	0.000638	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—urinary bladder cancer	7.97e-05	0.000637	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.96e-05	0.000636	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—urinary bladder cancer	7.94e-05	0.000634	CcSEcCtD
Pomalidomide—Vertigo—Doxorubicin—urinary bladder cancer	7.83e-05	0.000625	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—urinary bladder cancer	7.8e-05	0.000623	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—urinary bladder cancer	7.75e-05	0.000619	CcSEcCtD
Pomalidomide—Infection—Epirubicin—urinary bladder cancer	7.63e-05	0.00061	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—urinary bladder cancer	7.6e-05	0.000607	CcSEcCtD
Pomalidomide—Nervous system disorder—Epirubicin—urinary bladder cancer	7.53e-05	0.000602	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.52e-05	0.000601	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.48e-05	0.000597	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—urinary bladder cancer	7.46e-05	0.000596	CcSEcCtD
Pomalidomide—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.43e-05	0.000593	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—urinary bladder cancer	7.43e-05	0.000593	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—urinary bladder cancer	7.42e-05	0.000592	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—urinary bladder cancer	7.39e-05	0.00059	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.36e-05	0.000588	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—urinary bladder cancer	7.32e-05	0.000585	CcSEcCtD
Pomalidomide—Confusional state—Doxorubicin—urinary bladder cancer	7.17e-05	0.000573	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—urinary bladder cancer	7.14e-05	0.00057	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.09e-05	0.000566	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—urinary bladder cancer	7.08e-05	0.000565	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—urinary bladder cancer	7.06e-05	0.000564	CcSEcCtD
Pomalidomide—Pain—Methotrexate—urinary bladder cancer	7.02e-05	0.000561	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7e-05	0.000559	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.97e-05	0.000557	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.96e-05	0.000556	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—urinary bladder cancer	6.95e-05	0.000555	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—urinary bladder cancer	6.9e-05	0.000552	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	6.87e-05	0.000549	CcSEcCtD
Pomalidomide—Dyspnoea—Epirubicin—urinary bladder cancer	6.85e-05	0.000547	CcSEcCtD
Pomalidomide—Feeling abnormal—Methotrexate—urinary bladder cancer	6.77e-05	0.00054	CcSEcCtD
Pomalidomide—Decreased appetite—Epirubicin—urinary bladder cancer	6.68e-05	0.000533	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.63e-05	0.00053	CcSEcCtD
Pomalidomide—Fatigue—Epirubicin—urinary bladder cancer	6.62e-05	0.000529	CcSEcCtD
Pomalidomide—Pain—Epirubicin—urinary bladder cancer	6.57e-05	0.000525	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—urinary bladder cancer	6.57e-05	0.000525	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—urinary bladder cancer	6.49e-05	0.000518	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.48e-05	0.000517	CcSEcCtD
Pomalidomide—Insomnia—Doxorubicin—urinary bladder cancer	6.43e-05	0.000514	CcSEcCtD
Pomalidomide—Dyspnoea—Doxorubicin—urinary bladder cancer	6.34e-05	0.000506	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—urinary bladder cancer	6.33e-05	0.000506	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—urinary bladder cancer	6.18e-05	0.000494	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.14e-05	0.00049	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—urinary bladder cancer	6.13e-05	0.00049	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—urinary bladder cancer	6.08e-05	0.000486	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—urinary bladder cancer	6.08e-05	0.000486	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—urinary bladder cancer	6.07e-05	0.000485	CcSEcCtD
Pomalidomide—Hypersensitivity—Methotrexate—urinary bladder cancer	6.05e-05	0.000483	CcSEcCtD
Pomalidomide—Asthenia—Methotrexate—urinary bladder cancer	5.89e-05	0.000471	CcSEcCtD
Pomalidomide—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.86e-05	0.000468	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—urinary bladder cancer	5.81e-05	0.000464	CcSEcCtD
Pomalidomide—Hypersensitivity—Epirubicin—urinary bladder cancer	5.66e-05	0.000452	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—urinary bladder cancer	5.62e-05	0.000449	CcSEcCtD
Pomalidomide—Diarrhoea—Methotrexate—urinary bladder cancer	5.62e-05	0.000449	CcSEcCtD
Pomalidomide—Asthenia—Epirubicin—urinary bladder cancer	5.51e-05	0.00044	CcSEcCtD
Pomalidomide—Pruritus—Epirubicin—urinary bladder cancer	5.44e-05	0.000434	CcSEcCtD
Pomalidomide—Dizziness—Methotrexate—urinary bladder cancer	5.43e-05	0.000434	CcSEcCtD
Pomalidomide—Diarrhoea—Epirubicin—urinary bladder cancer	5.26e-05	0.00042	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.24e-05	0.000418	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	5.22e-05	0.000825	CbGpPWpGaD
Pomalidomide—Vomiting—Methotrexate—urinary bladder cancer	5.22e-05	0.000417	CcSEcCtD
Pomalidomide—Rash—Methotrexate—urinary bladder cancer	5.18e-05	0.000413	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—urinary bladder cancer	5.17e-05	0.000413	CcSEcCtD
Pomalidomide—Headache—Methotrexate—urinary bladder cancer	5.14e-05	0.000411	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	5.1e-05	0.000806	CbGpPWpGaD
Pomalidomide—Asthenia—Doxorubicin—urinary bladder cancer	5.1e-05	0.000407	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—urinary bladder cancer	5.08e-05	0.000406	CcSEcCtD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	5.04e-05	0.000796	CbGpPWpGaD
Pomalidomide—Pruritus—Doxorubicin—urinary bladder cancer	5.03e-05	0.000402	CcSEcCtD
Pomalidomide—Vomiting—Epirubicin—urinary bladder cancer	4.88e-05	0.00039	CcSEcCtD
Pomalidomide—Nausea—Methotrexate—urinary bladder cancer	4.88e-05	0.00039	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—urinary bladder cancer	4.86e-05	0.000389	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	4.86e-05	0.000767	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	4.86e-05	0.000767	CbGpPWpGaD
Pomalidomide—Rash—Epirubicin—urinary bladder cancer	4.84e-05	0.000387	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—urinary bladder cancer	4.84e-05	0.000387	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.83e-05	0.000762	CbGpPWpGaD
Pomalidomide—Headache—Epirubicin—urinary bladder cancer	4.81e-05	0.000384	CcSEcCtD
Pomalidomide—PTGS2—Disease—GSTO2—urinary bladder cancer	4.81e-05	0.00076	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	4.72e-05	0.000746	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	4.72e-05	0.000746	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	4.71e-05	0.000744	CbGpPWpGaD
Pomalidomide—Dizziness—Doxorubicin—urinary bladder cancer	4.7e-05	0.000376	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—TP53—urinary bladder cancer	4.67e-05	0.000738	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.67e-05	0.000737	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.66e-05	0.000736	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.64e-05	0.000733	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.62e-05	0.00073	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	4.62e-05	0.00073	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.6e-05	0.000727	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	4.6e-05	0.000727	CbGpPWpGaD
Pomalidomide—Nausea—Epirubicin—urinary bladder cancer	4.56e-05	0.000365	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	4.56e-05	0.00072	CbGpPWpGaD
Pomalidomide—Vomiting—Doxorubicin—urinary bladder cancer	4.52e-05	0.000361	CcSEcCtD
Pomalidomide—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	4.5e-05	0.000712	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	4.5e-05	0.000711	CbGpPWpGaD
Pomalidomide—Rash—Doxorubicin—urinary bladder cancer	4.48e-05	0.000358	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—urinary bladder cancer	4.48e-05	0.000358	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—urinary bladder cancer	4.45e-05	0.000356	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.44e-05	0.000702	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NCOR1—urinary bladder cancer	4.43e-05	0.0007	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	4.41e-05	0.000696	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	4.4e-05	0.000695	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	4.39e-05	0.000693	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	4.37e-05	0.00069	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.32e-05	0.000682	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—urinary bladder cancer	4.29e-05	0.000678	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	4.28e-05	0.000676	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	4.27e-05	0.000674	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	4.26e-05	0.000673	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	4.25e-05	0.000671	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	4.23e-05	0.000668	CbGpPWpGaD
Pomalidomide—Nausea—Doxorubicin—urinary bladder cancer	4.22e-05	0.000337	CcSEcCtD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	4.21e-05	0.000666	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	4.2e-05	0.000664	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—urinary bladder cancer	4.2e-05	0.000663	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	4.15e-05	0.000655	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	4.14e-05	0.000654	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	4.14e-05	0.000654	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	4.03e-05	0.000637	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTO2—urinary bladder cancer	4.03e-05	0.000636	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NAT1—urinary bladder cancer	4.03e-05	0.000636	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.98e-05	0.000629	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—KRAS—urinary bladder cancer	3.96e-05	0.000626	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.96e-05	0.000626	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	3.94e-05	0.000623	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	3.94e-05	0.000623	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	3.92e-05	0.00062	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	3.91e-05	0.000618	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.87e-05	0.000611	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.87e-05	0.000611	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.79e-05	0.000598	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—urinary bladder cancer	3.76e-05	0.000593	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SLC19A1—urinary bladder cancer	3.74e-05	0.000591	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.72e-05	0.000588	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	3.68e-05	0.000582	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PRSS3—urinary bladder cancer	3.64e-05	0.000576	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	3.63e-05	0.000573	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	3.61e-05	0.00057	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.59e-05	0.000567	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.58e-05	0.000565	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.56e-05	0.000562	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—urinary bladder cancer	3.52e-05	0.000556	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	3.52e-05	0.000556	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CDK4—urinary bladder cancer	3.49e-05	0.000552	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HDAC4—urinary bladder cancer	3.48e-05	0.000549	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	3.44e-05	0.000544	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.38e-05	0.000534	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	3.32e-05	0.000525	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	3.32e-05	0.000524	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	3.29e-05	0.00052	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	3.28e-05	0.000518	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	3.28e-05	0.000518	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	3.26e-05	0.000515	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	3.2e-05	0.000506	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.18e-05	0.000502	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PPARG—urinary bladder cancer	3.17e-05	0.000501	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	3.13e-05	0.000495	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PRSS3—urinary bladder cancer	3.05e-05	0.000482	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CREBBP—urinary bladder cancer	3.05e-05	0.000482	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.03e-05	0.000478	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	3.01e-05	0.000476	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.99e-05	0.000472	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.98e-05	0.000471	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	2.89e-05	0.000457	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.89e-05	0.000456	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.88e-05	0.000455	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.86e-05	0.000452	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.85e-05	0.000451	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.85e-05	0.000451	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.82e-05	0.000446	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.78e-05	0.00044	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LIG1—urinary bladder cancer	2.76e-05	0.000436	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—RHOA—urinary bladder cancer	2.76e-05	0.000436	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.75e-05	0.000434	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.74e-05	0.000434	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.67e-05	0.000422	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	2.61e-05	0.000412	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ERBB2—urinary bladder cancer	2.55e-05	0.000403	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.45e-05	0.000387	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TYMP—urinary bladder cancer	2.44e-05	0.000385	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.43e-05	0.000383	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	2.4e-05	0.00038	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.39e-05	0.000378	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.39e-05	0.000378	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	2.35e-05	0.000371	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.34e-05	0.00037	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.34e-05	0.00037	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.34e-05	0.00037	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	2.28e-05	0.00036	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NAT1—urinary bladder cancer	2.28e-05	0.00036	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.24e-05	0.000354	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.23e-05	0.000352	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.22e-05	0.000351	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.21e-05	0.000349	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NAT2—urinary bladder cancer	2.21e-05	0.000349	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—urinary bladder cancer	2.19e-05	0.000346	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.16e-05	0.000342	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.12e-05	0.000334	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ENO2—urinary bladder cancer	2.11e-05	0.000333	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	2.08e-05	0.000329	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EP300—urinary bladder cancer	2.08e-05	0.000328	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.05e-05	0.000323	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.04e-05	0.000323	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—SRC—urinary bladder cancer	2.02e-05	0.000319	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RBX1—urinary bladder cancer	2e-05	0.000315	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.97e-05	0.000311	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.95e-05	0.000308	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.9e-05	0.000301	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.89e-05	0.000299	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	1.88e-05	0.000296	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.86e-05	0.000293	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—JAG1—urinary bladder cancer	1.79e-05	0.000282	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	1.77e-05	0.00028	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—urinary bladder cancer	1.77e-05	0.00028	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.76e-05	0.000279	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.76e-05	0.000279	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.76e-05	0.000278	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.76e-05	0.000278	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.75e-05	0.000277	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.73e-05	0.000273	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	1.73e-05	0.000273	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.71e-05	0.00027	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.7e-05	0.000268	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.68e-05	0.000266	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KRAS—urinary bladder cancer	1.67e-05	0.000264	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.66e-05	0.000262	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.61e-05	0.000254	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.58e-05	0.00025	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.57e-05	0.000248	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.56e-05	0.000247	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.45e-05	0.000229	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.42e-05	0.000225	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—urinary bladder cancer	1.42e-05	0.000225	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.39e-05	0.00022	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.38e-05	0.000219	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.38e-05	0.000218	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.37e-05	0.000216	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.35e-05	0.000213	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.33e-05	0.000211	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.33e-05	0.000209	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NCOR1—urinary bladder cancer	1.3e-05	0.000206	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.25e-05	0.000198	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.25e-05	0.000198	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.25e-05	0.000197	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERCC2—urinary bladder cancer	1.22e-05	0.000193	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.21e-05	0.000192	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.2e-05	0.00019	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.19e-05	0.000187	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—urinary bladder cancer	1.15e-05	0.000182	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.15e-05	0.000181	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TERT—urinary bladder cancer	1.15e-05	0.000181	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.14e-05	0.000179	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.1e-05	0.000174	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.09e-05	0.000172	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.09e-05	0.000172	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.08e-05	0.00017	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.07e-05	0.000168	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR3—urinary bladder cancer	1.05e-05	0.000166	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.04e-05	0.000165	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.02e-05	0.000162	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.01e-05	0.000159	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	9.98e-06	0.000158	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ENO2—urinary bladder cancer	9.98e-06	0.000158	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.92e-06	0.000157	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	9.68e-06	0.000153	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	9.64e-06	0.000152	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—urinary bladder cancer	9.63e-06	0.000152	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.53e-06	0.000151	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CREBBP—urinary bladder cancer	8.96e-06	0.000142	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTP1—urinary bladder cancer	8.41e-06	0.000133	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	8.32e-06	0.000131	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RHOA—urinary bladder cancer	8.1e-06	0.000128	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NQO1—urinary bladder cancer	8.05e-06	0.000127	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TYMS—urinary bladder cancer	7.81e-06	0.000123	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARG—urinary bladder cancer	7.81e-06	0.000123	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.81e-06	0.000123	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NCOR1—urinary bladder cancer	7.72e-06	0.000122	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTM1—urinary bladder cancer	7.72e-06	0.000122	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	7.7e-06	0.000122	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	7.7e-06	0.000122	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CREBBP—urinary bladder cancer	7.5e-06	0.000119	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB2—urinary bladder cancer	7.5e-06	0.000119	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	7.47e-06	0.000118	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GPX1—urinary bladder cancer	7.4e-06	0.000117	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ERCC2—urinary bladder cancer	7.26e-06	0.000115	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—urinary bladder cancer	6.83e-06	0.000108	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.81e-06	0.000108	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	6.71e-06	0.000106	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.49e-06	0.000103	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—urinary bladder cancer	6.41e-06	0.000101	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTEN—urinary bladder cancer	6.4e-06	0.000101	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TYMS—urinary bladder cancer	6.24e-06	9.85e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.21e-06	9.81e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	6.17e-06	9.74e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	6.17e-06	9.74e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EP300—urinary bladder cancer	6.1e-06	9.64e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SRC—urinary bladder cancer	5.93e-06	9.37e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GPX1—urinary bladder cancer	5.91e-06	9.33e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	5.8e-06	9.16e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARG—urinary bladder cancer	5.54e-06	8.74e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	5.45e-06	8.61e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTEN—urinary bladder cancer	5.36e-06	8.46e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CREBBP—urinary bladder cancer	5.32e-06	8.4e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—urinary bladder cancer	5.32e-06	8.4e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—urinary bladder cancer	5.2e-06	8.21e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.18e-06	8.18e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—EP300—urinary bladder cancer	5.11e-06	8.07e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—urinary bladder cancer	4.91e-06	7.76e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.81e-06	7.61e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.76e-06	7.52e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.76e-06	7.52e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.56e-06	7.2e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.47e-06	7.07e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARG—urinary bladder cancer	4.42e-06	6.98e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—urinary bladder cancer	4.35e-06	6.88e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	4.25e-06	6.71e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.21e-06	6.64e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—urinary bladder cancer	4.18e-06	6.6e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTEN—urinary bladder cancer	3.8e-06	6e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—EP300—urinary bladder cancer	3.62e-06	5.72e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	3.48e-06	5.49e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.41e-06	5.39e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.28e-06	5.18e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.03e-06	4.79e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—EP300—urinary bladder cancer	2.89e-06	4.57e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.68e-06	4.24e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.34e-06	3.7e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.23e-06	3.52e-05	CbGpPWpGaD
